INSERM U946, Fondation Jean-Dausset-CEPH , 27 rue Juliette Dodu, 75010 Paris, France.
J Natl Cancer Inst. 2010 Oct 20;102(20):1568-83. doi: 10.1093/jnci/djq363. Epub 2010 Sep 28.
Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes, and some variants of the melanocortin-1 receptor gene (MC1R), which is known to have a role in the pigmentation process. However, investigation of the associations of both MC1R variants and host phenotypes with melanoma risk has been limited.
We included 815 CDKN2A mutation carriers (473 affected, and 342 unaffected, with melanoma) from 186 families from 15 centers in Europe, North America, and Australia who participated in the Melanoma Genetics Consortium. In this family-based study, we assessed the associations of the four most frequent MC1R variants (V60L, V92M, R151C, and R160W) and the number of variants (1, ≥2 variants), alone or jointly with the host phenotypes (hair color, propensity to sunburn, and number of nevi), with melanoma risk in CDKN2A mutation carriers. These associations were estimated and tested using generalized estimating equations. All statistical tests were two-sided.
Carrying any one of the four most frequent MC1R variants (V60L, V92M, R151C, R160W) in CDKN2A mutation carriers was associated with a statistically significantly increased risk for melanoma across all continents (1.24 × 10(-6) ≤ P ≤ .0007). A consistent pattern of increase in melanoma risk was also associated with increase in number of MC1R variants. The risk of melanoma associated with at least two MC1R variants was 2.6-fold higher than the risk associated with only one variant (odds ratio = 5.83 [95% confidence interval = 3.60 to 9.46] vs 2.25 [95% confidence interval = 1.44 to 3.52]; P(trend) = 1.86 × 10(-8)). The joint analysis of MC1R variants and host phenotypes showed statistically significant associations of melanoma risk, together with MC1R variants (.0001 ≤ P ≤ .04), hair color (.006 ≤ P ≤ .06), and number of nevi (6.9 × 10(-6) ≤ P ≤ .02).
Results show that MC1R variants, hair color, and number of nevi were jointly associated with melanoma risk in CDKN2A mutation carriers. This joint association may have important consequences for risk assessments in familial settings.
携带细胞周期蛋白依赖性激酶抑制剂 2A(CDKN2A)种系突变与黑色素瘤的高风险相关。CDKN2A 突变的外显率受色素沉着特征、痣表型和一些黑素皮质素 1 受体基因(MC1R)变体的修饰,已知 MC1R 变体在色素沉着过程中起作用。然而,对 MC1R 变体和宿主表型与黑色素瘤风险的关联的研究一直受到限制。
我们纳入了来自欧洲、北美和澳大利亚的 15 个中心的 186 个家族中的 815 名 CDKN2A 突变携带者(473 名受影响者和 342 名未受影响者,患有黑色素瘤),他们参加了黑色素瘤遗传学联合会。在这项基于家族的研究中,我们评估了四个最常见的 MC1R 变体(V60L、V92M、R151C 和 R160W)以及变体数量(1 个,≥2 个变体)单独或与宿主表型(头发颜色、晒伤倾向和痣数量)一起与 CDKN2A 突变携带者黑色素瘤风险的关联。使用广义估计方程估计和检验这些关联。所有统计检验均为双侧检验。
在 CDKN2A 突变携带者中携带四个最常见的 MC1R 变体(V60L、V92M、R151C、R160W)中的任何一个变体与黑色素瘤的风险增加相关,在所有大陆均具有统计学意义(1.24×10(-6)≤P≤.0007)。与 MC1R 变体数量增加相关的黑色素瘤风险增加也呈一致模式。至少有两个 MC1R 变体相关的黑色素瘤风险是仅一个变体相关的风险的 2.6 倍(比值比=5.83[95%置信区间=3.60 至 9.46]比 2.25[95%置信区间=1.44 至 3.52];P(趋势)=1.86×10(-8))。MC1R 变体与宿主表型的联合分析显示黑色素瘤风险与 MC1R 变体(.0001≤P≤.04)、头发颜色(.006≤P≤.06)和痣数量(6.9×10(-6)≤P≤.02)呈统计学显著关联。
结果表明,MC1R 变体、头发颜色和痣数量与 CDKN2A 突变携带者的黑色素瘤风险相关。这种联合关联可能对家族环境中的风险评估具有重要意义。